Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues

Table 2

Characteristics of randomized studies comparing different antiplatelet strategies in association with direct oral anticoagulants or vitamin K antagonists (VKA).

Study	Antiplatelet treatment				ACS patients (n/N)	Primary efficacy endpoint	Primary efficacy result	Primary safety endpoint	Primary safety result
	Strategy shorter DAPT	Months	Strategy longer DAPT	Months
PIONEER AF-PCI	Rivaroxaban 15 + clopidogrel (ticagrelor/prasugrel allowed < 15%) or	12 months	VKA + DAPT	1, 6, or 12 months	1096/1415	Death from cardiovascular cause, myocardial infarction, or stroke	—	Clinically significant bleeding
WOEST	Causes myocardial infarction or stroke							All bleeding events (TIMI criteria)
ENTRUST-AF PCI	VKA + clopidogrel	1 month after BMS and 12 months after DES	VKA + ASA + clopidogrel	1 month after BMS and 12 months after DES	155/563	Stroke, death, myocardial infarction, stent thrombosis, and target vessel revascularization	—	Clinically relevant bleeding	—
RE-DUAL PCI	Edoxaban 60 mg + clopidogrel ticagrelor/prasugrel allowed < 10%)	12 months	VKA + ASA + clopidogrel ticagrelor/prasugrel allowed < 15%)	12 months (ASA min 1 month)	777/1506	Cardiovascular death, stroke, systemic embolic events (SEE), myocardial infarction, and definite stent thrombosis	—	ISTH major or clinically relevant nonmajor bleedings
AUGUSTUS	Dabigatran 110 or 150 mg BID + clopidogrel or ticagrelor	6 months	VKA + ASA + clopidogrel or ticagrelor	6 months	1744/3489	Thromboembolic events, death, or unplanned revascularization	—	ISTH major or clinically relevant nonmajor bleedings